Bengaluru CRDMO — drug discovery, development & manufacturing plus a specialty ingredients business.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 8 | 8 | 9 | 114 | 112 | 112 | 112 | 112 |
| Reserves | 413 | 693 | 1.3k | 1.6k | 1.8k | 2.3k | 2.6k | 2.9k |
| Borrowings | 159 | 100 | 35 | 126 | 239 | 113 | 108 | 54 |
| Other Liabilities | 207 | 232 | 228 | 148 | 235 | 284 | 424 | 333 |
| Total Liabilities | 787 | 1.0k | 1.6k | 2.0k | 2.4k | 2.8k | 3.3k | 3.4k |
| AssetsFixed Assets | 306 | 361 | 329 | 449 | 483 | 705 | 769 | 783 |
| CWIP | 50 | 19 | 154 | 164 | 345 | 297 | 263 | 264 |
| Investments | 99 | 209 | 273 | 499 | 472 | 433 | 545 | 1.0k |
| Other Assets | 333 | 445 | 863 | 902 | 1.1k | 1.4k | 1.7k | 1.4k |
| Total Assets | 787 | 1.0k | 1.6k | 2.0k | 2.4k | 2.8k | 3.3k | 3.4k |
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 166 | 278 | 333 | 306 | 140 | 271 | 844 |
| Cash from Investing | -109 | -196 | -205 | -376 | -221 | -147 | -702 |
| Cash from Financing | -48 | -63 | 181 | 64 | -77 | -136 | -40 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — |
| Free Cash Flow | 119 | 159 | 307 | 112 | -156 | 12 | 637 |
| FCF Margin | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (76.3×) and current (77.2×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 31.3% growth and a 76× exit, ₹791 only delivers your return if you pay ₹1,437. The price is currently baking in 18% growth.
EPS grows 31.3%/yr for 5 years, then fades to 6% over 2, exits at 76×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 31.3% | 13.46 |
| FY28 | 31.3% | 17.67 |
| FY29 | 31.3% | 23.20 |
| FY30 | 31.3% | 30.46 |
| FY31 | 31.3% | 40.00 |
| FY32 | 18.6% ·fade | 47.46 |
| FY33 | 6.0% ·fade | 50.31 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.